Skip to main content
SpringerLink
Log in

Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Risedronate is widely used clinically to treat osteoporosis, Paget’s disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects. This study was designed to evaluate the effect of deoxycholic acid derivatives on the permeability and oral bioavailability of risedronate by increasing its lipophilicity and affinity to bile transporters. We synthesized two bile acid derivatives, N α-deoxycholyl-l-lysyl-methylester (DCK) and N α-deoxycholyl-l-lysyl-hydroxide (HDCK) as oral absorption enhancers. After ionic complex formation with the bile acid derivatives, the complexes were characterized by powder X-ray diffraction. Their artificial membrane permeabilities and bioavailabilities in rats were investigated in comparison with pure risedronate. Complex formation with DCK or HDCK demonstrated that risedronate existed in an amorphous form in the complex. A physical complex of risedronate with DCK enhanced the apparent membrane permeability of risedronate significantly but pure risedronate was not permeable. An in vivo study revealed that the C max and AUClast of risedronate/DCK (1:2) complex were 1.92- and 2.64-fold higher than those of pure risedronate, respectively. Thus, the risedronate/DCK complex can improve the oral absorption of risedronate and patient compliance by reducing dose frequency and adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Bittner, B., C. McIntyre, H. Tian, K. Tang, N. Shah, W. Phuapradit, H. Ahmed, H. Chokshi, M. Infeld, N. Fotaki, H. Ma, A. Portron, P. Jordan, and J. Schmidt. 2012. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie 67: 233–241.

    CAS  PubMed  Google Scholar 

  • Blumentals, W.A., S.T. Harris, R.E. Cole, L. Huang, and S.L. Silverman. 2009. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Annals of Pharmacotherapy 43: 577–585.

    Article  CAS  PubMed  Google Scholar 

  • Coxon, F.P., K. Thompson, and M.J. Rogers. 2006. Recent advances in understanding the mechanism of action of bisphosphonates. Current Opinion in Pharmacology 6: 307–312.

    Article  CAS  PubMed  Google Scholar 

  • Cramer, J.A., M.M. Amonkar, A. Hebborn, and R. Altman. 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinion 21: 1453–1460.

    Article  CAS  PubMed  Google Scholar 

  • Delmas, P.D., M.R. McClung, J.R. Zanchetta, A. Racewicz, C. Roux, C.L. Benhamou, Z. Man, R.A. Eusebio, J.F. Beary, D.E. Burgio, E. Matzkin, and S. Boonen. 2008. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42: 36–42.

    Article  CAS  PubMed  Google Scholar 

  • Dunn, C.J., and K.L. Goa. 2001. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61: 685–712.

    Article  CAS  PubMed  Google Scholar 

  • Eastell, R., I. Barton, R.A. Hannon, A. Chines, P. Garnero, and P.D. Delmas. 2003. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research 18: 1051–1056.

    Article  CAS  PubMed  Google Scholar 

  • Eriksen, E.F., F. Melsen, E. Sod, I. Barton, and A. Chines. 2002. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620–625.

    Article  CAS  PubMed  Google Scholar 

  • Ezra, A., A. Hoffman, E. Breuer, I.S. Alferiev, J. Mönkkönen, N. El Hanany-Rozen, G. Weiss, D. Stepensky, I. Gati, H. Cohen, S. Törmälehto, G.L. Amidon, and G. Golomb. 2000. A peptide prodrug approach for improving bisphosphonate oral absorption. Journal of Medicinal Chemistry 43: 3641–3652.

    Article  CAS  PubMed  Google Scholar 

  • Hadji, P., J.R. Zanchetta, L. Russo, C.P. Recknor, K.G. Saag, F.E. McKiernan, S.L. Silverman, J. Alam, R.T. Burge, J.H. Krege, M.C. Lakshmanan, D.N. Masica, B.H. Mitlak, and J.L. Stock. 2012. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International 23: 2141–2150.

    Article  CAS  PubMed  Google Scholar 

  • Hamilton, B., K. McCoy, and H. Taggart. 2003. Tolerability and compliance with risedronate in clinical practice. Osteoporosis International 14: 259–262.

    CAS  PubMed  Google Scholar 

  • Hounslow, A.M., J. Carran, R.J. Brown, D. Rejman, M. Blackburn, and D.J. Watts. 2008. Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs. Journal of Medicinal Chemistry 51: 4170–4178.

    Article  CAS  PubMed  Google Scholar 

  • Ilter, E., H. Karalok, E.C. Tufekci, and O. Batur. 2006. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 9: 129–134.

    Article  CAS  PubMed  Google Scholar 

  • Janner, M., R.C. Mühlbauer, and H. Fleisch. 1991. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcified Tissue International 49: 280–2803.

    Article  CAS  PubMed  Google Scholar 

  • Jeon, O.C., S.R. Hwang, T.A. Al-Hilal, J.W. Park, H.T. Moon, S. Lee, J.H. Park, and Y. Byun. 2013. Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharmaceutical Research 30: 959–967.

    Article  CAS  PubMed  Google Scholar 

  • Kavanagh, K.L., K. Guo, J.E. Dunford, X. Wu, S. Knapp, F.H. Ebetino, M.J. Rogers, R.G. Russell, and U. Oppermann. 2006. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of Sciences of the United States of America 16: 7829–7834.

    Article  Google Scholar 

  • Kim, S.K., K. Kim, S. Lee, K. Park, J.H. Park, I.C. Kwon, K. Choi, C.Y. Kim, and Y. Byun. 2005. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface Plasmon resonance. Journal of Pharmaceutical and Biomedical Analysis 39: 861–870.

    Article  CAS  PubMed  Google Scholar 

  • Kim, S.K., D.Y. Lee, E. Lee, Y.K. Lee, C.Y. Kim, H.T. Moon, and Y. Byun. 2007. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anticoagulant. Journal of Control Release 120: 4–10.

    Article  CAS  Google Scholar 

  • Kim, S.K., S. Lee, S. Jin, H.T. Moon, O.C. Jeon, D.Y. Lee, and Y. Byun. 2010. Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex. Molecular Pharmaceutics 7: 708–717.

    Article  CAS  PubMed  Google Scholar 

  • Kimmel, D.B. 2007. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. Journal of Dental Research 86: 1022–1033.

    Article  CAS  PubMed  Google Scholar 

  • Lambrinoudaki, I., G. Christodoulakos, and D. Botsis. 2006. Bisphosphonates. Annals of the New York Academy of Sciences 1092: 397–402.

    Article  CAS  PubMed  Google Scholar 

  • Lee, S., S.K. Kim, D.Y. Lee, S.Y. Chae, and Y. Byun. 2006. Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats. Antimicrobial Agents and Chemotherapy 50: 1869–1871.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lee, S., J. Lee, D.Y. Lee, S.K. Kim, Y. Lee, and Y. Byun. 2005. A new drug carrier, N-alpha-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine. Diabetologia 48: 405–411.

    Article  CAS  PubMed  Google Scholar 

  • Lin, J.H. 1996. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75–85.

    Article  CAS  PubMed  Google Scholar 

  • Lin, J.H., I.W. Chen, and F.A. deLuna. 1994. On the absorption of alendronate in rats. Journal of Pharmaceutical Sciences 83: 1741–1746.

    Article  CAS  PubMed  Google Scholar 

  • Lin, J.H., D.E. Duggan, I.W. Chen, and R.L. Ellsworth. 1991. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metabolism and Disposition 19: 926–932.

    CAS  PubMed  Google Scholar 

  • Luckman, S.P., D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 13: 581–589.

    Article  CAS  PubMed  Google Scholar 

  • McClung, M.R., C.L. Benhamou, Z. Man, W. Tlustochowicz, J.R. Zanchetta, R. Eusebio, A.M. Balske, E. Matzkin, W.P. Olszynski, R. Recker, and P.D. Delmas. 2013. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcified Tissue International 92: 59–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mitchell, D.Y., W.H. Barr, R.A. Eusebio, K.A. Stevens, F.P. Duke, D.A. Russell, J.D. Nesbitt, J.H. Powell, and G.A. Thompson. 2001. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharmaceutical Research 18: 166–170.

    Article  CAS  PubMed  Google Scholar 

  • Mitchell, D.Y., R.A. Eusebio, N.A. Sacco-Gibson, K.A. Pallone, S.C. Kelly, J.D. Nesbitt, C.P. Brezovic, G.A. Thompson, and J.H. Powell. 2000. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. Journal of Clinical Pharmacology 40: 258–265.

    Article  CAS  PubMed  Google Scholar 

  • Mitchell, D.Y., M.A. Heise, K.A. Pallone, M.E. Clay, J.D. Nesbitt, D.A. Russell, and C.W. Melson. 1999. The effect of dosing regimen on the pharmacokinetics of risedronate. British Journal of Clinical Pharmacology 48: 536–542.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mortensen, L., P. Charles, P.J. Bekker, J. Digennaro, and C.C. Johnston Jr. 1998. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus 1 year of follow-up. Journal of Clinical Endocrinology and Metabolism 83: 396–402.

    CAS  PubMed  Google Scholar 

  • Nam, S.H., J.H. Jeong, X. Che, K.E. Lim, H. Nam, J.S. Park, and J.Y. Choi. 2012. Topically administered risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model. Bone 50: 149–155.

    Article  CAS  PubMed  Google Scholar 

  • Park, J.W., S.R. Hwang, O. Jeon, H.T. Moon, and Y. Byun. 2013. Enhanced oral absorption of ibandronate via complex formation with bile acid derivative. Journal of Pharmaceutical Sciences 102: 341–346.

    Article  CAS  PubMed  Google Scholar 

  • Reszka, A.A., and G.A. Rodan. 2003. Mechanism of action of bisphosphonates. Current Osteoporosis Reports 1: 45–52.

    Article  PubMed  Google Scholar 

  • Rodan, G.A., and T.J. Martin. 2000. Therapeutic approaches to bone diseases. Science 289: 1508–1514.

    Article  CAS  PubMed  Google Scholar 

  • Siris, E.S., A.A. Chines, R.D. Altman, J.P. Brown, C.C. Johnston Jr, R. Lang, M.R. McClung, L.E. Mallette, P.D. Miller, W.G. Ryan, F.R. Singer, J.R. Tucci, R.A. Eusebio, and P.J. Bekker. 1998. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. Journal of Bone and Mineral Research 13: 1032–1038.

    Article  CAS  PubMed  Google Scholar 

  • Yates, J. 2013. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporosis International 24: 253–262.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Research Funds of Mokpo National University in 2013.

Author information

Authors and Affiliations

  1. Natural Medicine Research Institute, College of Pharmacy, Mokpo National University, 1666 Youngsan-ro, Cheonggye-myeon, Muan-gun, Jeonnam, 534-729, Republic of Korea

    Jin Woo Park

  2. Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Republic of Korea

    Youngro Byun

  3. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Republic of Korea

    Youngro Byun

Authors
  1. Jin Woo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youngro Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jin Woo Park or Youngro Byun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, J.W., Byun, Y. Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats. Arch. Pharm. Res. 37, 1560–1569 (2014). https://doi.org/10.1007/s12272-013-0297-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-013-0297-x

Keywords

Search

Navigation